10x Genomics Inc Ordinary Shares - Class A TXG
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TXG is a good fit for your portfolio.
News
-
10x Genomics to Report First Quarter 2024 Financial Results on April 30, 2024
-
10x Genomics Commercially Launches Visium HD Spatial Gene Expression Assay
-
10x Genomics Expands Xenium Menu with Multi-Modal Cell Segmentation Kit and Immuno-Oncology Gene Panel
-
Johnson Fistel Announces Investigation of 10x Genomics (TXG) for Potential Securities Law Violations
-
10x Genomics Begins Commercial Shipments of Chromium GEM-X Products
-
10x Genomics to Present at the 44th Annual TD Cowen Health Care Conference
-
10x Genomics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Outlook for 2024
-
10x Genomics Expands Leadership in Single Cell Analysis with Launch of GEM-X Technology
Trading Information
- Previous Close Price
- $27.52
- Day Range
- $26.30–27.14
- 52-Week Range
- $26.30–63.57
- Bid/Ask
- $26.20 / $28.63
- Market Cap
- $3.21 Bil
- Volume/Avg
- 1.1 Mil / 1.5 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 5.21
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
- Sector
- Healthcare
- Industry
- Health Information Services
- Stock Style Box
- Small Value
- Total Number of Employees
- 1,259
- Website
- https://www.10xgenomics.com
Comparables
Valuation
|
Metric
|
TXG
|
RVTY
|
TIHE
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 22.08 | — |
Price/Book Value | 4.42 | 1.61 | — |
Price/Sales | 5.21 | 4.66 | — |
Price/Cash Flow | — | 19.11 | — |
Price/Earnings
TXG
RVTY
TIHE
Financial Strength
|
Metric
|
TXG
|
RVTY
|
TIHE
|
|---|---|---|---|
Quick Ratio | 3.96 | 1.54 | — |
Current Ratio | 4.69 | 2.07 | — |
Interest Coverage | −8,049.58 | 2.12 | — |
Quick Ratio
TXG
RVTY
TIHE
Profitability
|
Metric
|
TXG
|
RVTY
|
TIHE
|
|---|---|---|---|
Return on Assets (Normalized) | −11.53% | 1.95% | — |
Return on Equity (Normalized) | −14.67% | 3.52% | — |
Return on Invested Capital (Normalized) | −14.55% | 2.47% | — |
Return on Assets
TXG
RVTY
TIHE
Health Information Services Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
GEHC
| GE HealthCare Technologies Inc Common Stock | — | Tpkxvp | $39.4 Bil | |
VEEV
| Veeva Systems Inc Class A | Ttbrksyclc | Ntmyh | $32.4 Bil | |
SOLV
| Solventum Corp | — | Vwwphbx | $11.0 Bil | |
MTHRF
| M3 Inc | — | Glmwfg | $8.3 Bil | |
MTHRY
| M3 Inc ADR | — | Fwkcgkm | $8.2 Bil | |
PMCUF
| Pro Medicus Ltd | — | Hhswtfx | $7.2 Bil | |
HQY
| HealthEquity Inc | — | Cwvpynl | $6.8 Bil | |
RCM
| R1 RCM Inc | — | Cyppy | $5.0 Bil | |
DOCS
| Doximity Inc Class A | — | Yrhgt | $4.5 Bil | |
EVH
| Evolent Health Inc Class A | — | Qztd | $3.3 Bil |